Comparison of the One-year Outcomes of Conbercept Therapy Between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy




To compare the outcomes of conbercept therapy between two different angiographic subtypes of polypoidal choroidal vasculopathy (PCV).


Fifty-eight patients of PCV were classified into two phenotypes according to indocyanine green angiography (ICGA). In type 1, both feeder and draining vessels are visible on ICGA and network vessels are numerous. In type 2, neither feeder nor draining vessels are detectable and the number of network vessels is small. The patients were treated with intravitreal conbercept (IVC) for 3 months. Additional IVC was given at subsequent monthly visits, if needed. The patients were followed-up for 12 months, and changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage, and number of polypoidal lesions were evaluated.


The mean BCVA in type 2 PCV (15.92±9.7614.10±9.07) achieved a significantly greater improvement in than the type 1 (14.10±9.07) at month 12 (p < 0.01). And the mean CRT decrease was numerically greater in type 2 (120.44± 73.81) compared with type 1 (106.48 ± 72.33) at month 6 (p < 0.01), and greater in type 2 (130.21± 76.28) compared with type 1 (111.67 ± 79.57) at month 9 (p < 0.01). There was no significant difference between the two groups for the decrease in SRF thickness, PED height, and regression of polyps from month 3 to 12(p > 0.05).


Classification systems for PCV will show differences in presentation, natural history or response to anti-VEGF treatment and might therefore provide a new key to the choice of treatment of the disease.


Cheng Yong
Beijing, China
Email :
Cell Phone: +8615120071105
Work Phone: +8601088325413